Physician profile
Whitney Stone Sharp
NPI 1952017139
$8,481.42
in general payments reported to CMS, 2019-2025
25 companies · $3,995 in 2025
The $3,995 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,811 · 2024: $2,676 · 2025: $3,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,019 · Consulting Fee: $1,125 · Education: $315 · Travel and Lodging: $21.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,019.30 |
| Consulting Fee | $1,125.00 |
| Education | $315.24 |
| Travel and Lodging | $21.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,171.64 | 2023-2025 | Tremfya |
| Ucb, INC. | $995.27 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $878.55 | 2023-2025 | |
| Lilly USA, LLC | $852.03 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $705.18 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $541.02 | 2023-2025 | Blu-U, Odomzo, Ilumya |
| Genzyme Corporation | $490.31 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $458.26 | 2023-2025 | |
| Amgen INC. | $450.19 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $315.37 | 2023-2025 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Incyte Corporation | $93.40 | 2023-2024 | Opzelura |
| Pfizer INC. | $85.85 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $59.96 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $52.88 | 2023-2025 | Adbry, Anzupgo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $38.18 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $33.06 | 2024 | Ycanth |
| Kyowa Kirin, INC. | $30.00 | 2023-2024 | Poteligeo |
| Convatec INC. | $23.22 | 2023 | |
| Dermavant Sciences, INC. | $21.05 | 2024 | Vtama |
| Mayne Pharma Commercial LLC | $18.78 | 2024 | |
| Genentech USA, INC. | $17.95 | 2023 | Erivedge |
| Botanix Sb INC | $17.50 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $16.66 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $15.12 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.